Injectable tirzepatide is the only approved form, known commercially as Zepbound for weight management
But with retatrutide, the effects of GLP-1 and GIP balance that out
Ashley (00:07:44): The greasy fries, right
Monitor for any GI symptoms (rare at this dose)
The Key Takeaways: Most common: Nausea (43%), manageable with dietary changes and timing Unique: Dysesthesia (20.9%), mild tingling sensations, not seen with Wegovy/Mounjaro Timeline: Worst during dose escalation (weeks 116), significant improvement after Discontinuation: 18.2% in TRIUMPH-4, 11.3% in TRIUMPH-1 the general obesity population tolerates it better than the osteoarthritis cohort Reversible: Stopping medication reverses side effects For most people with obesity especially severe obesity the 28.328.7% weight loss and associated health benefits outweigh the temporary discomfort during the first few months
In my practice, I constantly encounter patients who feel theyve hit a wall